Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Amphivena Therapeutics, Inc.

Affimed Therapeutics, Ag

Affimed Gmbh

Other

Deutsches Krebsforschungszentrum

Dade Behring Marburg Gmbh

Behring Diagnostics Gmbh

University of the Witwatersrand, Johannesburg

Affemed Gmbh

Affirmed Gmbh

Deutsches Krehsforschungszentrum Stiftung Des Offentlichen Rechts

Siemens Healthcare Diagnostics Products Gmbh

Melvyn Little

Stefan Knackmuss

Uwe Reusch

Frank Breitling

Iris Klewinghaus

Stefan Dubel

Kristina Ellwanger

Ivica Fucek

Eugene Zhukovsky

Michael Braunagel

Michael Weichel

Sergey Kipriyanov

Vera Molkenthin

Luke Evnin

Jeanmarie Guenot

Erich Rajkovic

Fabrice Le Gall

Lori Kunkel

Judith A Fox

Karin Hoffmann

Stefan D&uuml;bel

Claudia Wall

Sergej Kipriyanov

Karlheinz Peter

Frank Berthold Breitling

Peter Röttgen

Stefan Dübel

Thomas Seehaus

Peter Roettgen

Meike Schwarz

Patrick Fuchs

Stefan Franz Thomas Weiss

Marc Saul Weinberg

Vera Mick

Claudia Buettner

Markus Eser

Fionnuala McAleese-Eser

Gerd Moldenhauer

Claudia Haas

Khashayarsha Khazaie

Schirrmacher Volker

Stefanie Gotter

Hans-Jurgen Rode

Katarina Jovanovic

Danielle Gonsavles

Bianca Da Costa Dias

Claudia Linhard

Fionnuala Mcaleese-Eser

Eugene Zhukovksy

Sergej Kiprijanov

Stefan Hans Knackmuss

MSergey Kipriyanov

Stefan H J Knackmuss

Stefan Weiss

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33cancers, diseases and conditions such as acute myeloid leukemia (AML).

Bispecific CD33 and CD3 binding proteins

This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.

Antibody binding sites specific for EGFRvIII

The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.

CD3 binding domains

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc&#x3b3;RIIIA), and in particular binding molecules that specifically bind the A form Fc&#x3b3;RIII but do not bind to the B form of Fc&#x3b3;RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.

Anti-CD16 binding molecules

The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (&#x3b2;) and gamma (&#x3b3;) secretases and amyloid beta peptide (A&#x3b2;), and also relates to a method of reducing A&#x3b2; shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.

Compounds for use in the treatment of Alzheimer's disease

The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.

Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa

The present invention relates to a multivalent Fantibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fantibody construct and a method of producing the Fantibody constructs as well as their use.

Multivalent antibody constructs

Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.

Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types

Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa

The present invention relates to multivalent Fantibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fantibody construct and a method of producing the Fantibody constructs as well as their use.

A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.

Phagemid for antibody screening

Growing community of inventors

Neckargemund, Germany

Melvyn Little